Considerations on implementing diagnostic markers into clinical decision making in bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 4, 2010, Pages 441-448

  Lotan, Yair ^a   Shariat, Shahrokh F ^b   Schmitz Dräger, Bernd J ^c   Sanchez Carbayo, Marta ^d   Jankevicius, Feliksas ^e   Racioppi, Marco ^f   Minner, Sarah J P ^g   Stöhr, Brigitte ^h   Bassi, Pier Francesco ^f   Grossman, H Barton ⁱ  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Urologie   (Germany)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e VILNIUS UNIVERSITY   (Lithuania)

^f CATHOLIC UNIVERSITY   (Italy)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h UNIVERSITY OF INNSBRUCK   (Austria)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bladder cancer; Urine based tumor markers

Indexed keywords

BIOLOGICAL MARKER; NUCLEAR MATRIX PROTEIN 22;

BLADDER CANCER; CANCER DIAGNOSIS; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL EXAMINATION; CLINICAL PRACTICE; CLINICAL RESEARCH; COST BENEFIT ANALYSIS; CYTOLOGY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; HEALTH SURVEY; HEMATURIA; HUMAN; MICTURITION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCREENING; VALIDATION PROCESS; CLINICAL TRIAL (TOPIC); URINARY BLADDER NEOPLASMS; VALIDATION STUDY;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; URINARY BLADDER NEOPLASMS; VALIDATION STUDIES AS TOPIC;

EID: 77953850928     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.11.004     Document Type: Review

References (54)

1. Herman M.P., Svatek R.S., Lotan Y., et al. Urine-based biomarkers for the early detection and surveillance of non-muscle-invasive bladder cancer. Minerva Urol Nefrol 60 (2008) 217-235
2. Babjuk M.A., Oosterlinck W., Sylvester R., et al. Guidelines on TaT1 (non-muscle-invasive) bladder cancer. In: Aus G., Hanus T., Irani J., et al. (Eds). Arnhem, The Netherlands: European Association of Urology: Guidelines (2008), EAU, Arnhem, The Netherlands 1-22
3. Bensalah K., Montorsi F., and Shariat S.F. Challenges of cancer biomarker profiling. Eur Urol 52 (2007) 1601-1609
4. Lotan Y., Shariat S.F., and NMP22 Study Group. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU Int 101 (2008) 1362-1367
5. Shariat S.F., Karakiewicz P.I., Suardi N., et al. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: A critical analysis of the literature. Clin Cancer Res 14 (2008) 4400-4407
6. Shariat S.F., Margulis V., Lotan Y., et al. Nomograms for bladder cancer. Eur Urol 54 (2008) 41-53
7. Vickers A.J., Jang K., Sargent D., et al. Systematic review of statistical methods used in molecular marker studies in cancer. Cancer 112 (2008) 1862-1868
8. Lotan Y., and Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses. Urology 61 (2003) 109-118
9. Lokeshwar V.B., Habuchi T., Grossman H.B., et al. Bladder tumor markers beyond cytology: Bladder tumor markers consensus panel. Urology 66 Suppl 6A (2005) 35-63
10. Shariat S.F., Canto E.I., Kattan M.W., et al. Beyond prostate-specific antigen: New serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 6 (2004) 58-72
11. Goebell P.J., Groshen S., and Schmitz-Dräger B.J. Guidelines for development of diagnostic markers in bladder cancer. W J Urol 26 (2008) 5-11
12. McShane L.M., Altman D.G., Sauerbrei W., et al., Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor Marker prognostic studies (REMARK). Nat Clin Pract Urol 2 (2005) 416-422
13. Shariat S.F., Zippe C., Lüdecke G., et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma of the bladder. J Urol 173 (2005) 1518-1525
14. Lotan Y., Capitanio U., Shariat S.F., et al. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int 103 (2009) 1368-1374
15. Steiner H., Bergmeister M., Verdorfer I., et al. Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int 102 (2008) 291-296
16. Madeb R., and Messing E.M. Long-term outcome of home dipstick testing for hematuria. World J Urol 26 (2008) 19-24
17. Lotan Y., Elias K., Svatek R.S., et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol 182 (2009) 52-57
18. Schmitz-Dräger B.J., Tirsar L.-A., Schmitz-Dräger C., et al. Immunocytology in the assessment of patients with gross hematuria. Br J Urol 101 (2008) 455-458
19. Grossfeld G.D., Litwin M.S., Wolf J.S., et al. Evaluation of asymptomatic microscopic hematuria in adults: The American Urological Association best practice policy. Part I: Definition, detection, prevalence, and etiology. Urology 57 (2001) 599-603
20. Mariani A.J., Mariani M.C., Macchioni C., et al. The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 141 (1989) 350-355
21. Cohen R.A., and Brown R.S. Clinical practice. Microscopic hematuria. N Engl J Med 348 (2003) 2330-2338
22. Schmitz-Dräger B.J., Beiche B., Tirsar L.-A., et al. Immunocytology in the assessment of patients with asymptomatic microhematuria. Eur Urol 51 (2007) 1582-1588
23. Schmitz-Dräger B.J., Tirsar L.-A., Schmitz-Dräger C., et al. Immunocytology in the assessment of patients with asymptomatic hematuria. W J Urol 26 (2008) 31-37
24. Yoder B.J., Skacel M., Hedgepeth R., et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: A prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 127 (2007) 295-301
25. Grossman H.B., Soloway M., Messing E., et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295 (2006) 299-305
26. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 26 (2008) 646-651
27. Konety B., and Lotan Y. Urothelial bladder cancer: Biomarkers for detection and screening. BJU Int 102 (2008) 1234-1241
28. Soloway M.S. Expectant treatment of small, recurrent, low-grade, noninvasive tumors of the urinary bladder. Urol Oncol 24 (2006) 58-61
29. Grossman H.B., Messing E., Soloway M., et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293 (2005) 810-816
30. Messing E., Madeb M.R., Young T., et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 107 (2006) 2173-2179
31. Lachaine J., Valiquette L., and Crott R. Economic evaluation of NMP22 in the management of bladder cancer. Can J Urol 7 (2000) 974-980
32. Lodde M., Mian C., Comploj E., et al. uCyt+ test: Alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology 67 (2006) 950-954
33. Lotan Y., Bensalah K., Ruddell T., et al. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 179 (2008) 2164-2169
34. Skacel M., Fahmy M., Brainard J.A., et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 169 (2003) 2101-2105
35. Yoder B.J., Skacel M., Hedgepeth R., et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: A prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 127 (2007) 295-301
36. Schröder F.H., Hugosson J., Roobol M.J., et al., ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009) 1320-1328
37. Andriole G.L., Crawford E.D., Grubb III R.L., et al., PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360 (2009) 1310-1319
38. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2,596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
39. Gofrit O.N., Zorn K.C., Silvestre J., et al. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer. Urol Oncol 26 (2008) 246-249
40. Schneeweiss S., Kriegmair M., and Stepp H. Is everything all right if nothing seems wrong?. A simple method of assessing the diagnostic value of endoscopic procedures when a gold standard is absent. J Urol 161 (1999) 1116-1119
41. Hungerhuber E., Stepp H., Kriegmair M., et al. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 69 (2007) 260-264
42. Svatek R.S., Lee D., and Lotan Y. Correlation of office-based cystoscopy and cytology with histologic diagnosis: How good is the reference standard?. Urology 66 (2005) 65-68
43. Paez A., Coba J.M., Murillo N., et al. Reliability of the routine cytological diagnosis in bladder cancer. Eur Urol 35 (1999) 228-232
44. Raitanen M.P., Aine R., Rintala E., et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 41 (2002) 284-289
45. Nabi G., Greene D.R., and O'Donnell M. How important is urinary cytology in the diagnosis of urological malignancies?. Eur Urol 43 (2003) 632-636
46. Nabi G., Greene D., and O'Donnell M.O. Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of hematuria: How to follow up?. J Clin Pathol 57 (2004) 365-368
47. Raitanen M.P., Aine R., Kylmala T., et al. The dilemma of suspicious urine cytology in patients being followed for bladder cancer. Ann Chir Gynaecol 90 (2001) 256-259
48. Nieder A.M., Lotan Y., Nuss G.R., et al. Are patients with hematuria appropriately referred to Urology?. A multi-institutional questionnaire based survey. Urol Oncol (2008, Dec 19) [Epub ahead of print]
49. Johnson E.K., Daignault S., Zhang Y., et al. Patterns of hematuria referral to urologists: Does a gender disparity exist?. Urology 72 (2008) 498-502
50. Lotan Y., Svatek R.S., and Sagalowsky A.I. Should we screen for bladder cancer in a high-risk population?. A cost per life-year saved analysis. Cancer 107 (2006) 982-990
51. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch released April 2005, based on the November 2004 submission.
52. Mandrekar S.J., and Sargent D.J. Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 27 (2009) 4027-4034
53. Mandrekar S.J., Grothey A., Goetz M.P., et al. Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics 5 (2005) 317-325
54. Mandrekar S.J., and Sargent D.J. Clinical trial designs for predictive biomarker validation: One size does not fit all. J Biopharm Stat 19 (2009) 530-542